Strona główna・Stock List・MediciNova Inc

MediciNova Inc

Closed

SectorHealthcare

1.31 1.55

Buy Sell

Overview

Share price change

24h

Current

Min

1.28

Max

1.31

Key metrics
By Trading Economics
Income	216K -2.6M
Sales	35K 187K
EPS	-0.05
Profit margin	-1,383.144
Employees	6
EBITDA	312K -2.5M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+501.5% upside

Dividends
By Acuity
Next Earnings	12 sie 2026

Market Stats
By TradingEconomics
Market Cap	-4.4M 65M
Previous open	-0.24
Previous close	1.31

News Sentiment

By Acuity

43%

57%

135 / 340 Ranking in Healthcare

MediciNova Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31 lip 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30 lip 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29 lip 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28 lip 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27 lip 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24 lip 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23 lip 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21 lip 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Peer Comparison

Price change

MediciNova Inc Forecast

Price Target

By TipRanks

501.5% upside

12 Months Forecast

Average 8 USD 501.5%

High 10 USD

Low 6 USD

Based on 2 Wall Street analysts offering 12 month price targets forMediciNova Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to MediciNova Inc - Dist in the past 3 months.

Sentiment

By Acuity

135 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.